Acorda Therapeutics, Inc. (ACOR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Acorda Therapeutics, Inc. (ACOR) trades at $0.661 with AI Score 42/100 (Grade C). Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders. Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for ACOR: ACOR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ACOR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ACOR: 1/3 scored disciplines lean bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Acorda Therapeutics, Inc. (ACOR) Healthcare & Pipeline Overview
Acorda Therapeutics, Inc. develops and commercializes therapies for neurological disorders, primarily focusing on multiple sclerosis and Parkinson's disease. The company's key products include Ampyra and Inbrija, addressing walking impairment in MS patients and OFF periods in Parkinson's disease, respectively. They operate in the specialty pharmaceutical market, facing competition from both established and emerging players.
What Is the Investment Thesis for ACOR?
Acorda Therapeutics faces significant challenges and opportunities. The company's reliance on Ampyra sales, despite generic competition, presents a risk. However, the continued commercialization of Inbrija in Europe offers a potential growth driver. The success of their pipeline products, such as the ARCUS product for acute migraine, rHIgM22 for MS, and Cimaglermin alfa for heart failure, is crucial for future revenue streams. The company's high gross margin of 60.9% indicates pricing power, but the negative profit margin of -215.0% raises concerns about operational efficiency and expense management. Investors should closely monitor the progress of clinical trials, regulatory approvals, and the impact of generic competition on Ampyra sales.
Based on FMP financials and quantitative analysis
ACOR Key Highlights
- Market capitalization of $0.00B reflects the company's current financial challenges and market perception.
- Gross margin of 60.9% indicates strong pricing power for its existing products.
- Negative profit margin of -215.0% highlights significant operational inefficiencies and high expenses.
- Beta of 1.46 suggests higher volatility compared to the overall market.
- The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS).
Who Are ACOR's Competitors?
ACOR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| LSDI Lucy Scientific Discovery Inc. | $0.51 | -23.29% | 47 | |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.14 | +0.21% | $40.3M | 61 |
| MNNGF Baijin Life Science Holdings Limited | $0.07 | +0.00% | $58.0M | 63 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| SHIEF Shield Therapeutics plc | $0.08 | +0.00% | $84.8M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ACOR's Key Strengths?
- Proprietary drug formulations (Ampyra and Inbrija).
- Established presence in the MS market.
- High gross margin.
- Focus on neurological disorders.
What Are ACOR's Weaknesses?
- Reliance on Ampyra sales.
- Negative profit margin.
- Limited product pipeline.
- Generic competition for Ampyra.
What Could Drive ACOR Stock Higher?
- Clinical trial results for ARCUS product for acute migraine.
- Regulatory approval decisions for new drug applications.
- Commercialization efforts for Inbrija in European markets.
- Development of rHIgM22 for multiple sclerosis.
- Strategic partnerships and licensing agreements.
What Are the Key Risks for ACOR?
- Financial-distress signal — its Altman Z-Score of -32.72 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Generic competition for Ampyra.
- Regulatory setbacks for pipeline products.
- Pricing pressures from healthcare providers.
- Competition from other pharmaceutical companies.
- High operating expenses and negative profit margin.
What Are the Growth Opportunities for ACOR?
- Expansion of Inbrija in European Markets: Acorda has the opportunity to further penetrate the European market with Inbrija, its treatment for OFF periods in Parkinson's disease. The Parkinson's disease market is projected to reach $5.6 billion by 2028, offering a substantial growth opportunity. Successful commercialization and market penetration in key European countries could significantly boost revenue. This expansion relies on effective marketing strategies, favorable reimbursement policies, and positive clinical outcomes.
- Advancement of ARCUS Product for Acute Migraine: Acorda is developing ARCUS product for the treatment of acute migraine. The migraine treatment market is estimated to reach $3.5 billion by 2027. Successful development and regulatory approval of ARCUS could provide a significant new revenue stream. This opportunity depends on positive clinical trial results, regulatory approval, and effective market launch.
- Development of rHIgM22 for Multiple Sclerosis: Acorda is developing rHIgM22, a treatment for MS, which has completed Phase I clinical trial. The MS market is projected to reach $30 billion by 2028. Positive clinical trial results and regulatory approval could position rHIgM22 as a valuable asset. This opportunity hinges on demonstrating efficacy and safety in subsequent clinical trials.
- Commercialization of Cimaglermin alfa for Heart Failure: Acorda is developing Cimaglermin alfa for heart failure patients. The heart failure market is estimated to reach $18 billion by 2029. Successful development and regulatory approval of Cimaglermin alfa could provide a significant new revenue stream. This opportunity depends on positive clinical trial results, regulatory approval, and effective market launch.
- Strategic Partnerships and Licensing Agreements: Acorda can pursue strategic partnerships and licensing agreements to expand its pipeline and commercial reach. Collaborating with other pharmaceutical companies or research institutions can provide access to new technologies, drug candidates, and markets. These partnerships can accelerate the development and commercialization of new therapies, reducing risk and increasing potential returns. The success of this strategy depends on identifying and securing mutually beneficial partnerships.
What Opportunities Does ACOR Have?
- Expansion of Inbrija in European markets.
- Advancement of ARCUS product for acute migraine.
- Development of rHIgM22 for multiple sclerosis.
- Strategic partnerships and licensing agreements.
What Threats Does ACOR Face?
- Generic competition for Ampyra.
- Regulatory challenges.
- Pricing pressures from healthcare providers.
- Competition from other pharmaceutical companies.
What Are ACOR's Competitive Advantages?
- Proprietary drug formulations (Ampyra and Inbrija).
- Patent protection for key products.
- Established relationships with healthcare providers.
- Specialized focus on neurological disorders.
What Does ACOR Do?
Acorda Therapeutics, Inc., founded in 1995 and headquartered in Ardsley, New York, is a biopharmaceutical company dedicated to developing and commercializing therapies for neurological disorders. The company's primary focus is on addressing unmet needs in multiple sclerosis (MS) and Parkinson's disease. Acorda's flagship product, Ampyra (dalfampridine), is an oral medication designed to improve walking in patients with MS. Ampyra is also marketed as Fampyra in Europe, Asia, and the Americas. In addition to Ampyra, Acorda markets Inbrija, a treatment for OFF periods in Parkinson's disease, specifically in Europe. The company is also developing ARCUS product for the treatment of acute migraine, rHIgM22, which has completed Phase I clinical trial for the treatment of MS, and Cimaglermin alfa for heart failure patients. Acorda has a collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda's strategy involves a combination of internal research and development, strategic collaborations, and licensing agreements to expand its pipeline and commercial reach. The company's focus on neurological disorders positions it within a growing market driven by an aging population and increasing prevalence of these conditions.
What Products and Services Does ACOR Offer?
- Develops and commercializes therapies for neurological disorders.
- Markets Ampyra (dalfampridine) to improve walking in patients with multiple sclerosis (MS).
- Markets Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
- Develops ARCUS product for the treatment of acute migraine.
- Develops rHIgM22 for the treatment of MS.
- Develops Cimaglermin alfa for heart failure patients.
How Does ACOR Make Money?
- Develops and commercializes proprietary pharmaceutical products.
- Generates revenue through the sale of prescription drugs.
- Partners with other companies for development and commercialization.
- Focuses on neurological disorders, specifically MS and Parkinson's disease.
What Industry Does ACOR Operate In?
Acorda Therapeutics operates in the specialty pharmaceutical sector, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The market for neurological disorder treatments is expanding due to the aging global population and increasing prevalence of conditions like multiple sclerosis and Parkinson's disease. Companies like Acorda face competition from both established pharmaceutical giants and smaller, innovative biotech firms. The industry is also influenced by factors such as patent expirations, generic drug approvals, and pricing pressures from healthcare providers and payers.
Who Are ACOR's Key Customers?
- Patients with multiple sclerosis (MS).
- Patients with Parkinson's disease.
- Healthcare providers who prescribe Acorda's medications.
- Pharmacies that dispense Acorda's medications.
F-Score 3/9Financial Health
Acorda Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -32.72 places it in the distress zone, a signal of elevated financial risk.
ACOR Valuation & Market Position
Relative to its peer group, ACOR's quantitative score of 42/100 is below the peer average of 59/100.
Company Profile
Acorda Therapeutics, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Ardsley, US. The company is led by CEO Ron Cohen. ACOR has traded publicly since 2006.
ACOR Financials
Bull Case vs Bear Case
Bull Case
- Proprietary drug formulations (Ampyra and Inbrija).
- Established presence in the MS market.
- High gross margin.
- Focus on neurological disorders.
Bear Case
- Reliance on Ampyra sales.
- Negative profit margin.
- Limited product pipeline.
- Generic competition for Ampyra.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ACOR Latest News
No recent news available for ACOR.
ACOR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ACOR.
Price Targets
Wall Street price target analysis for ACOR.
ACOR MoonshotScore
What does this score mean?
The MoonshotScore rates ACOR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Ron Cohen
CEO
Ron Cohen has served as the CEO of Acorda Therapeutics, Inc. He has extensive experience in the biotechnology and pharmaceutical industries. His background includes leadership roles in research and development, as well as commercialization. He has been instrumental in guiding Acorda's strategic direction and product development efforts. He is responsible for managing 102 employees.
Track Record: Under Ron Cohen's leadership, Acorda Therapeutics has focused on developing and commercializing therapies for neurological disorders. Key achievements include the development and launch of Ampyra and Inbrija. Strategic decisions have involved navigating regulatory challenges and competition in the pharmaceutical market. He has overseen the company through various stages of growth and market dynamics.
Acorda Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for ACOR?
ACOR holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders. Their key products target multiple sclerosis and Parkinson's …
What does Acorda Therapeutics, Inc. do?
Acorda Therapeutics, Inc. is a biopharmaceutical company that focuses on developing and commercializing therapies for neurological disorders. The company's primary products include Ampyra (dalfampridine), used to improve walking in patients with multiple sclerosis (MS), and Inbrija, a treatment for OFF periods in Parkinson's disease, primarily marketed in Europe.
What do analysts say about ACOR stock?
Analyst coverage of Acorda Therapeutics, Inc. is limited, reflecting the company's small market capitalization and financial challenges. Key valuation metrics, such as price-to-earnings ratio, are often not applicable due to negative earnings. Growth considerations revolve around the success of Inbrija in Europe and the potential of pipeline products.
What are the main risks for ACOR?
Acorda Therapeutics, Inc. faces several significant risks. The primary risk is the generic competition for Ampyra, which has eroded sales and profitability. Regulatory risks associated with the development and approval of new drugs are also a concern. Pricing pressures from healthcare providers and payers can impact revenue. Competition from larger pharmaceutical companies with greater resources poses a threat.
How does Acorda Therapeutics, Inc. manage patent expiration risks?
Acorda Therapeutics, Inc. faces patent expiration risks, particularly concerning Ampyra. To mitigate these risks, the company employs several strategies. These include developing new formulations or delivery methods for existing drugs, pursuing patent extensions where possible, and diversifying the product pipeline through research and development of new therapies.
What is Acorda Therapeutics, Inc.'s drug pipeline status?
Acorda Therapeutics, Inc.'s drug pipeline includes several products in various stages of development. The ARCUS product is being developed for the treatment of acute migraine. rHIgM22 has completed Phase I clinical trial for the treatment of MS. Cimaglermin alfa is being developed for heart failure patients. The success of these pipeline products is critical for Acorda's future growth.
What are the key factors to evaluate for ACOR?
Acorda Therapeutics, Inc. (ACOR) holds an AI score of 42/100 (low). Not financial advice.
How frequently does ACOR data refresh on this page?
ACOR's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ACOR's recent stock price performance?
Acorda Therapeutics, Inc. (ACOR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary drug formulations (Ampyra and Inbrija). See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recently available information.
- AI analysis is pending and may provide additional insights.
- The competitive landscape is subject to change.
- Clinical trial outcomes are uncertain.